Drug Trial Radar · NCT05583838
A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts
Last checked: Nov 20, 2026Latest source record: Apr 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
157
Actual
Start
Nov 22, 2022
Primary completion
Feb 28, 2024
Study completion Jul 16, 2024
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Second Hospital of Hebei Medical University; Xijing Hospital; The Affiliated Hospital of Inner Mongolia Medical University; The Second Affiliated Hospital of Kunming Medical University; Second Affiliated Hospital of Guangzhou Medical University; Shaanxi Provincial People's Hospital; Henan Cancer Hospital; North China University of Science and Technology; The Second Affiliated Hospital of Dalian Medical University; Second Hospital of Shanxi Medical University; The Second Affiliated Hospital of Harbin Medical University; Shenyang Sunshine Pharmaceutical Co., LTD.; First Affiliated Hospital of Xinjiang Medical University; People's Hospital of Xinjiang Uygur Autonomous Region; Kashgar 1st People's Hospital; Xi'an Central Hospital; Beijing Public Health Foundation; Yuyao People's Hospital
- First posted
- Oct 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TE-ITP study: Compare the efficacy and safety of optimized rhTPO treatment versus Eltrombopag treatment in previously treated primary immune thrombocytopenia patients.
Conditions
- Previously Treated Primary Immune Thrombocytopenia
Interventions
rhTPODrug
initial therapy: rhTPO s.c, 300 or 600U/kg daily based on baseline platelet count; maintenance therapy: rhTPO s.c, 300 \~ 600U/kg every other day depends on platelet count.
EltrombopagDrug
initial therapy: Eltrombopag oral, 25 or 50mg daily based on baseline platelet count; maintenance therapy: Eltrombopag oral, 25 \~ 75mg daily or every other day depends on platelet count.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median time to achieve platelet count ≥50x10^9/L during 6 weeks observationTime frame: in 6 weeks treatment
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
the Second Hospital of HeBei Medical University
Shijiazhuang, Hebei, China
North China University of Science and Technology Affiliated Hospital
Tangshan, Heibei, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
Zhengzhou, Henan, China
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
The Second Hospital of Dalian Medical University
Dalian, Liaoning, China
Xi'an Central Hospital
Xi'an, Shaanxi, China
Xijing Hospital of the Fourth Military Medical University
Xi'an, Shaanxi, China
Shaanxi Provincial People's Hospital
Xi'an, Shaanxi, China
Chinese Academy of Medical Science and Blood Disease Hospital,CAMS & PUMC
Tianjin, Tianjin Municipality, China
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China
Kashgar District 1st People's Hospital
Kashgar, Xinjiang, China
People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, China
The first affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Yuyao People's Hospital of Zhejiang Province
Yuyao, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.